 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
8-10-2021
Insider Buy |
Marc D. Kozin
Director |
$23.66
CAGR »
|
$70,986.00
3,000 shares |
8-10-2021
Insider Buy |
Douglas Fambrough
President and CEO |
$22.10
CAGR »
|
$110,480.00
5,000 shares |
9-1-2020
Insider Buy |
Douglas Fambrough
President and CEO |
$18.06
CAGR »
|
$180,597.00
10,000 shares |
12-18-2017
Insider Buy |
Bain Capital Life Sciences Investors, LLC
Director and >10% Owner |
$7.00
CAGR »
|
$1,995,000.00
285,000 shares |
11-15-2016
Insider Buy |
Douglas Fambrough
Chief Executive Officer |
$3.71
CAGR »
|
$122,643.00
33,100 shares |
1-29-2014
Insider Buy |
Douglas Fambrough
Chief Executive Officer |
$15.00
CAGR »
|
$75,000.00
5,000 shares |
1-29-2014
Insider Buy |
David Madden
Director |
$15.00
CAGR »
|
$112,500.00
7,500 shares |
2-4-2014
Insider Buy |
Stephen J. Hoffman
Director and >10% Owner |
$15.00
CAGR »
|
$3,000,000.00
200,000 shares |
2-4-2014
Insider Buy |
Venture Partners V. LP Skyline
>10% Owner |
$15.00
CAGR »
|
$3,000,000.00
200,000 shares |
2-4-2014
Insider Buy |
RA CAPITAL MANAGEMENT, LLC
>10% Owner |
$15.00
CAGR »
|
$15,000,000.00
1,000,000 shares |
2-4-2014
Insider Buy |
James E. Flynn
>10% Owner |
$15.00
CAGR »
|
$15,000,000.00
1,000,000 shares |
Also See: Institutional Holders of DRNA
Also See: SEC filings
Below we present the annualized performance delivered by DRNA stock since 8-10-2021 (the date of the most recent
insider purchase). The performance of the investment from the time DRNA insider buying occurred is the ultimate
test of whether insiders were right about DRNA being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/11/2021 |
|
| End date: |
12/28/2021 |
|
| Start price/share: |
$21.29 |
|
| End price/share: |
$38.22 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
79.52% |
|
| Annualized Gain: |
208.81% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$17,952.00 |
|
| Years: |
0.38 |
|
DRNA Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent DRNA insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding DRNA
|
|
Free DRNA Email Alerts:
